Sign in Subscribe

phase-ii

A collection of 43 issues

ctDNA-guided chemotherapy strategy misses primary endpoint but reduces neurotoxicity

Skip to content The CRC Digest ◆ TRIAL DATA ctDNA-guided chemotherapy strategy misses primary endpoint but reduces neurotoxicity The phase 2 PEGASUS trial in 135 patients with high-risk stage II/III colon cancer used serial ctDNA testing to guide treatment intensity; 3-year disease-free survival was 58.4% in ctDNA-positive patients versus

Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer A phase II trial of 50 patients who had failed at least two prior therapies found median progression-free survival of 6.07 months and overall survival of 14.10 months, with

Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancer The REVERCE II trial randomized patients with RAS wild-type metastatic colorectal cancer to receive either regorafenib followed by anti-EGFR therapy or the reverse sequence, evaluating overall survival

Radiation plus dual checkpoint blockade evaluated in MSS metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Radiation plus dual checkpoint blockade evaluated in MSS metastatic disease A multi-institution phase II study enrolled patients with microsatellite stable metastatic colorectal cancer previously treated with oxaliplatin, 5-fluorouracil, and irinotecan to receive combined radiation therapy and nivolumab/ipilimumab, with the primary endpoint being

Pembrolizumab plus HER2-targeted ADC tested in pretreated HER2-positive mCRC

Skip to content The CRC Digest ▸ TREATMENT Pembrolizumab plus HER2-targeted ADC tested in pretreated HER2-positive mCRC A multicenter phase II study evaluated pembrolizumab combined with disitamab vedotin, an anti-HER2 antibody-drug conjugate, in patients with microsatellite stable, HER2-positive metastatic colorectal cancer who had received at least two prior lines of therapy.

Ifebemtinib Plus Garsorasib in KRAS G12C–Mutated Metastatic Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Ifebemtinib Plus Garsorasib in KRAS G12C–Mutated Metastatic Colorectal Cancer (Oncodaily) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

PEGASUS Phase 2 Trial Tests ctDNA-Guided Adjuvant Therapy in Colon Cancer

Skip to content The CRC Digest ◆ TRIAL DATA PEGASUS Phase 2 Trial Tests ctDNA-Guided Adjuvant Therapy in Colon Cancer A Phase 2 trial is evaluating whether circulating tumor DNA can guide adjuvant treatment decisions in colon cancer patients after surgery. (Oncodaily) This content is informational only and does not constitute

Phase II trial examines quality of life with panitumumab-based intensified regimen

Skip to content The CRC Digest Phase II trial examines quality of life with panitumumab-based intensified regimen The VOLFI trial analyzed health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI, noting that anti-EGFR antibodies like panitumumab are associated with a

Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease

Skip to content The CRC Digest ♥ LIVING WITH CRC Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer

Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case

Skip to content The CRC Digest Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case A case report from the AGMT mCRC Registry describes successful rechallenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. (Clinical Colorectal Cancer) This